The FDA has cleared a once-daily oral semaglutide treatment for adults with obesity or overweight and weight-related conditions, based on phase 3 OASIS 4 trial results demonstrating significant mean weight...
A new ACC/AHA clinical practice guideline on managing adults with congenital heart disease updates its 2018 recommendations by integrating evidence from 2017 to 2024 and emphasizing specialized...
A large systematic review and meta-analysis published in the Journal of the American Heart Association evaluated evidence from 155 studies worldwide, identifying strong associations between several viral...
A new multicenter randomized clinical trial published in JAMA evaluated whether consuming caffeinated coffee affects the recurrence of atrial fibrillation (AF) after cardioversion. The findings suggest that...
A phase 2 clinical trial found that ataciguat, a soluble guanylate cyclase activator, may slow aortic valve calcification and help preserve cardiac function in patients with moderate calcific aortic valve...
In a nationally representative cohort, adolescents and young adults with optimal cardiovascular health later had lower risks of gestational diabetes and hypertensive disorders of pregnancy than peers with...
New multicenter US data show that a single respiratory syncytial virus (RSV) vaccine dose protects against hospitalization in older adults, though effectiveness wanes over time and is lower in...
For patients with type 2 diabetes and established cardiovascular or kidney disease, daily oral semaglutide significantly lowered the risk of major adverse cardiovascular events during a median of 49.5...
Excess visceral fat, rather than BMI alone, is a key driver of cardiovascular risk in people with HIV receiving antiretroviral therapy. The study authors presented their findings at the Conference on...
